Most Read

The US Food and Drug Administration (FDA) has authorised additional doses of Pfizer-BioNTech and Moderna Covid-19 vaccines for certain people with compromised immune systems. The regulatory agency has

Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management. The firm plans to use the proceeds from the

The US Food and Drug Administration (FDA) has declined to approve AstraZeneca and FibroGen’s new drug application (NDA) for roxadustat to treat anaemia associated with chronic kidney disease

The US Food and Drug Administration (FDA) has granted priority review for Merck’s supplemental biologics license application (sBLA) for KEYTRUDA (pembrolizumab) as adjuvant therapy for patients with renal

Biotechnology firm Moderna and Canadian government have signed a memorandum of understanding (MoU) to construct a new messenger RNA (mRNA) vaccine manufacturing facility in Canada. The latest deal

INO-4800 features a particularly designed deoxyribonucleic acid (DNA) plasmid. To be injected intradermally with subsequent electroporation, INO-4800 carries the DNA plasmid directly into body cells. Inovio’s partner, Advaccine

This approval expands the total count of Covid-19 vaccines authorised in the country to five. Last week, J&J submitted an application seeking Emergency Use Authorization (EUA) for its

This vaccine candidate is based on the company’s Fc fusion protein platform. It stimulates a Th1/Th2 mixed immune response against the receptor-binding domain (RBD) of the SARS-CoV-2 spike

BRII-196 and BRII-198 are non-competing monoclonal antibodies obtained from convalesced Covid-19 patients. These antibodies neutralise SARS-CoV-2. The trial is funded by the NIH unit National Institute of Allergy